Product sheet

[redacted] HEK293-VEGF-TM | 305991

[redacted]

Description	[redacted] HEK293-VEGF-TM [redacted] 293 (HEK293) [redacted] VEGFR1 (FLT1) [redacted]-VEGFR2 (KDR), [redacted]. [redacted] HEK293-VEGF-TM [redacted]-VEGF, [redacted] T [redacted]-VEGF [redacted]-[redacted].
Organism	[redacted]
Tissue	[redacted]
Disease	[redacted]/[redacted]; [redacted] (HEK293)
Applications	[redacted] VEGF [redacted] (VEGF-TM); [redacted] VEGF; [redacted]; [redacted] ADCC/CDC;

[redacted]

Age	[redacted]
Gender	[redacted]
Morphology	[redacted]
Cell type	[redacted]
Growth properties	[redacted], [redacted]

[redacted]

Citation	HEK293-VEGF-TM ([redacted] Cytion: 305991)
Biosafety level	1
NCBI_TaxID	9606

[redacted] HEK293-VEGF-TM | 305991

CellosaurusAccession	CVCL_6G30
GMO Status	GMO-S1: [redacted] HEK293 [redacted] VEGF [redacted] (VEGF-TM) [redacted] VEGF [redacted]

[redacted] -[redacted]

Receptors expressed	VEGF-TM

[redacted]

Culture Medium	RPMI 1640, w: 2.0 mM [redacted], w: 2.0 g/L NaHCO3 ([redacted] Cytion 820700a)
Supplements	[redacted] 10% FBS, 1 mM [redacted], 10 mM HEPES, 1% NEAA. [redacted] Geneticin (G418-Sulfat) [redacted] 1 [redacted]
Dissociation Reagent	[redacted]-EDTA
Doubling time	[redacted]-24–36 [redacted]
Subculturing	[redacted]: [redacted] [redacted]-PBS [redacted] CO2’ [redacted] 2-3 [redacted]
Split ratio	1 [redacted] 5
Seeding density	2 [redacted] 4 x 10[redacted]
Fluid renewal	2 [redacted] 3 [redacted]
Post-Thaw Recovery	[redacted], [redacted] 1:2 [redacted] 1:3 [redacted] T25 [redacted] 24 [redacted] [redacted], [redacted]
Freeze medium	[redacted], [redacted] (FBS) + 10% DMSO [redacted] C

[redacted] HEK293-VEGF-TM | 305991

Thawing and Culturing Cells	1. [redacted] 2. [redacted] 3. [redacted] 4. [redacted] 5. [redacted] 6. [redacted] 7. [redacted] 8. [redacted]
Incubation Atmosphere	37°C, 5% $_{CO2}$, [redacted]
Shipping Conditions	[redacted]
Storage Conditions	[redacted]

[redacted]

Sterility	[redacted] PCR [redacted] [redacted]